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Summary
Objective: Calcitonin was recently reported to counter progression of cartilage degradation in an experimental model of osteoarthritis, and the
effects were primarily suggested to be mediated by inhibition of subchondral bone resorption. We investigated direct effects of calcitonin on
chondrocytes by assessing expression of the receptor and pharmacological effects on collagen type II degradation under ex vivo and in vivo
conditions.
Methods: Localization of the calcitonin receptor on articular chondrocytes was investigated by immunohistochemistry, and the expression by
reverse transcriptase polymerase chain reaction (RT-PCR). In bovine articular cartilage explants, cartilage degradation was investigated by
release of C-terminal telopeptides of collagen type II (CTX-II), induced by tumor necrosis factor-a (TNF-a) [20 ng/ml] and oncostatin M (OSM)
[10 ng/ml], with salmon calcitonin [0.0001e1 mM]. In vivo, cartilage degradation was investigated in ovariectomized (OVX) rats administered
with oral calcitonin [2 mg/kg calcitonin] for 9 weeks.
Results: The calcitonin receptor was identiﬁed in articular chondrocytes by immunohistochemistry and RT-PCR. Calcitonin concentration-
dependently increased cAMP levels in isolated chondrocytes. Explants cultured with TNF-a and OSM showed a 100-fold increase in CTX-II
release compared to vehicle-treated controls (P< 0.001). The degradation of type II collagen in these explants was concentration-dependently
inhibited by calcitonin, 65% protection at 10 nM calcitonin (P< 0.01). TNF-a and OSM induced a pronounced increase in matrix metallopro-
teinase (MMP) activity, which was strongly inhibited by calcitonin. In vivo, administration of salmon calcitonin to OVX rats resulted in signiﬁcant
(P< 0.001) decrease in CTX-II levels.
Conclusion: These results are the ﬁrst evidence of calcitonin receptor expression on articular chondrocytes and that the chondroprotective
effects of calcitonin might involve the inhibition of MMP expression.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is the most common joint disease and
a major cause of disability in people over 50 years of
age1. The hallmark of the disease is the progressive degen-
eration of articular cartilage accompanied by structural alter-
ations of subchondral bone. Currently, the clinical
management of OA is predominantly symptomatic and tar-
gets the alleviation of pain and joint stiffness, although there
are reports suggesting beneﬁts associated with the long-
term use of structure modifying agents such as glucos-
amine sulphate2.
The pathogenesis of OA is poorly understood, and
currently no treatments are available to counter the
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2006.75progression of OA or regenerate damaged cartilage. Devel-
opment of OA is most likely a combination of both subchon-
dral and articular cartilage metabolic imbalances resulting in
destructive joint diseases3,4. As a consequence, ideal treat-
ments may be those, which affect both subchondral bone
remodeling and at the same time directly inhibit the degra-
dation of articulate cartilage, or even promote articular car-
tilage matrix synthesis.
Calcitonin is an established anti-resorptive agent that has
been used for the treatment of osteoporosis for many
years5 and recently its application in the treatment of OA
has been discussed6. Although its effects on chondrocytes
and cartilage metabolism have not been investigated exten-
sively, observations suggest that it may stimulate cartilage
maturation and growth in vivo and ex vivo by stimulating
growth plate, pelvic and epiphyseal cartilage in various spe-
cies7e9 and stimulate proteoglycan synthesis and prolifera-
tion of isolated articular chondrocytes in vitro10.
Information of the direct effect of calcitonin on articular
cartilage degradation is very limited and until recently
restricted to isolated chondrocytes in vitro showing9
760 B. C. Sondergaard et al.: Calcitonin directly attenuates collagen type II degradationattenuation of collagenolytic activity11. Recently, the effect
of calcitonin was investigated in an experimental model of
OA, and calcitonin was shown to counter the progression
of joint lesions12,13, suggesting potential chondroprotective
effects. The authors implicated the inhibition of subchondral
bone turnover as a likely mechanism conveying this beneﬁ-
cial effect on cartilage12, albeit a direct effect of calcitonin on
cartilage formation was suggested13. However, a direct ef-
fect of calcitonin on degradation of intact articular cartilage
has not been systematically investigated.
Using both the articular cartilage explants model and the
rat in vivo model, we investigated (1) whether calcitonin in-
ﬂuences the cytokine-induced degradation of collagen type
II focusing on the involvement of matrix metalloproteinases
(MMPs), (2) whether calcitonin receptors are expressed in
chondrocytes, and (3) whether administration of calcitonin
to ovariectomized (OVX) rats can elicit changes in the se-
rum concentration of the CTX-II levels, a biomarker of car-
tilage degradation, in vivo.
Materials and methods
REAGENTS
All reagents used were of analytical grade. The culture
medium comprised Dulbecco’s Modiﬁed Eagle Medium
(D-MEM) containing penicillin and streptomycin (Life Tech-
nologies, US). Human recombinant oncostatin M (OSM,
human) and salmon calcitonin were from SigmaeAldrich
(UK), whereas human recombinant tumor necrosis factor-a
(TNF-a) was from R&D Systems, UK.
PREPARATION OF CARTILAGE EXPLANTS
Heifer stiﬂe joints from animals between 1 and 1.5 years
were used. Bovine articular cartilage explants, without ad-
herent calciﬁed cartilage, were carefully isolated using
a scalpel. The articular cartilage explants (16 4 mg w/w)
were rinsed three times in phosphate buffered saline
(PBS), weighed and placed in 96-well plates and cultured
in six replicates under the following serum-free conditions:
(1) in D-MEM only, (2) in D-MEM containing TNF-a and
OSM, and (3) in D-MEM containing TNF-a and OSM with
concentrations of salmon calcitonin [0.0001e1 mM]. To rep-
resent the situation of complete metabolic inactivation, ex-
plants were placed in cryotubes (Nunc, DK), frozen in
liquid N2, and thawed at 37(C in a water-bath for three
freeze-thaw cycles, and these explants were cultured in
D-MEM. Incubation was performed at 37(C, 5% CO2 apply-
ing constant shaking at 50 rpm. The conditioned medium
was fully replaced every 2nd and 3rd day and stored at
20(C until further analysis.
BIOCHEMICAL MARKERS OF CARTILAGE DEGRADATION
In conditioned medium
C-telopeptide fragments of type II collagen were mea-
sured using the pre-clinical (PC) CartiLaps ELISA (Nordic
Bioscience Diagnostics, DK); an enzyme-linked immunoas-
say based on mouse monoclonal antibodies targeting a six
amino acid neoepitope (EKGPDP) at the C-terminal telo-
peptide of collagen type II. The PC CartiLaps ELISA is
a modiﬁcation of the Urine CartiLaps ELISA14,15 optimized
for the detection of CTX-II fragments in animal urine and
culture medium. This assay has no signiﬁcant cross-reactivitywith type I collagen C-telopeptides (CTX-I)14,15. The de-
tection limit of the assay is 0.75 ng/ml and the intra- and
inter-assay coefﬁcients of variation (CV) in the PC Carti-
Laps assay are less than 6%.
In serum
A sandwich ELISA was used for estimation of cartilage
degradation in serum samples obtained from rodents (Nordic
Bioscience Diagnostics, DK). The assay is based on the
speciﬁc mouse monoclonal antibodies raised against the
amino acid sequence EKGPDP located at the C-terminal
telopeptide of collagen type II. The lowest detection limit is
1.1 pg/ml and the intra- and inter-assay CVs are below 8.0%.
CYCLIC AMP (cAMP)
The down-stream signaling of calcitonin was investigated
using the EIA kit from Amersham, US, for quantiﬁcation of
cAMP levels. Articular chondrocytes were isolated by enzy-
matic digestion with 0.5% trypsin (SigmaeAldrich, UK) for
30 min and 0.5% collagenase (Wako, DE) for 4 h at 37(C.
Chondrocytes were obtained after ﬁltration and centrifuga-
tion at 1100 g for 5 min. The pellet was resuspended in
a-MEM containing 10% fetal bovine serum (FBS), (Sigmae
Aldrich, UK), and sub-cultured for 5 days at 37(C, 5% CO2.
The cells were lifted, centrifuged, and cultured under se-
rum-free conditions for 24 h, and subsequently preinhibited
for 20 min with 100 mM 3-isobutyl-1-methylxanthine (IBMX),
and afterwards stimulated with 1 nMe1 mM calcitonin, or
1 mM forskolin for 20 min, all from SigmaeAldrich, UK.
After the ﬁrst passage and centrifugation the chondro-
cytes retrieve their spherical appearance. In order to con-
ﬁrm that the isolated chondrocytes still expressed the
calcitonin receptor, cytochemistry was performed using
mouse calcitonin receptor antibody (Abcam, UK), on chon-
drocytes cultured in parallel to the studies. Chondrocytes
with a ﬁbroblast-like appearance did not react with the cal-
citonin receptor antibody, whereas all the spherical cells did
(data not shown).
ZYMOGRAPHY
MMP expression and activity were determined by gelati-
nase zymography using 0.5 mg/ml of gelatine (SigmaeAl-
drich, UK) as a substrate in 7.5% SDS-polyacrylamide
gels. Samples were Molecular weight marker (Amersham,
US), conditioned medium from (1) vehicle, (2) TNF-a and
OSM, (3) TNF-a and OSMþ 1 mM calcitonin, and (4) TNF-
a and OSMþ 100 nM calcitonin treated articular cartilage
explants, cultured for 18 days. After electrophoresis, gels
were washed three times with 2.5% Triton X-100 in water
and then incubated overnight at 37(C in 0.1% Triton
X-100, 5 mM CaCl2, 1 mM ZnCl2, 3 mM NaN3, 50 mM Tris
pH 7.4 in a closed container. Gels were stained for 30 min
with 0.25% Coomassie R-250 (SigmaeAldrich, UK) in
10% acetic acid and 45% methanol and destained for
30 min with 20% acetic acid, 20% methanol, 17% ethanol,
and 0.6% diethylether. Gels were dried and scanned for
documentation.
IMMUNOHISTOCHEMISTRY
Bovine and human articular cartilage was tested parallel
for immunostaining. The unit of orthopedic surgery, Farsoe,
Denmark, supplied biopsies of femur and tibia plateau from
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the approval of the Scientiﬁc Ethical Committee, Danish
Ministry of Justice (approval number 01-051/02). The cul-
tured bovine articular cartilage explants were ﬁxed in
3.7% formaldehyde in PBS pH 7, parafﬁn embedded, and
subsequently sectioned. Pretreatment of sections in
10 mM Tris and 0.25 mM EDTA, pH 9.0 was used to en-
hance epitope presentation, after deparafﬁnization and re-
hydration. The cartilage sections were blocked for
nonspeciﬁc binding in Tris buffered saline with 5% casein
before incubation with the mouse calcitonin receptor anti-
body (Abcam, UK), or mouse monoclonal antibody from
the same subgroup IgG2a, (DAKOcytomation, DK) as a neg-
ative control. Peroxidase-labeled mouse Envision was used
as secondary antibody (DAKOcytomation, DK). Finally, the
immunoreactivity was visualized by liquid DABþ substrate
chromogen solution (3,30-diaminobenzidine chromogen so-
lution, SigmaeAldrich, UK) after which the slides were
rinsed in tap water. The nuclei were counterstained using
Ehrlich’s hematoxylin, and the slides were then dehydrated,
cleared and mounted with glass. Digital histographs were
taken using an Olympus BX60 microscope and an Olympus
C5050-zoom camera. As positive control the calcitonin re-
ceptor antibody was tested in parallel by cytochemistry on
human osteoclasts.
ISOLATION OF RNA
Preparation of articular chondrocytes
Bovine articular chondrocytes were isolated from the ex-
tra-cellular matrix by enzymatic digestion with 0.5% trypsin
(SigmaeAldrich, UK) for 30 min and 0.5% collagenase
(Wako, DE) for 4 h at 37(C. Chondrocytes were obtained
after ﬁltration and centrifugation at 1100 g for 5 min. The
pellet used to obtain total RNA from chondrocytes was pre-
pared using RNeasy Fibrous Tissue assay from Qiagen,
UK.
Human osteoclasts
Human osteoclasts were isolated using a Ficoll gradient
and CD14 bead sorting as previously described16,17. Brieﬂy,
peripheral blood obtained from healthy volunteers was sep-
arated by centrifugation on a Ficoll-Paque gradient. The
monocytes were puriﬁed by CD14 magnetic bead sorting
from the lymphocyte layer (Dynal Biotech, Norway). The
CD14 positive cells were then cultured in a-MEM containing
10% FBS, 25 ng/ml M-CSF and 25 ng/ml RANK-L (R&D
Systems, UK) until mature osteoclasts were present. Isola-
tion of RNA from osteoclasts was done using TRIzol-
reagent (Life Technologies, US), which is a modiﬁcation
to the single step RNA isolation methods developed by
Chomczynski and Sacchi18.
REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION
(RT-PCR)
Two micrograms of total RNA was used for reverse tran-
scription of total RNA to ssDNA and subsequent ampliﬁca-
tion using reagents from the Access RT-PCR system
(Promega, DE). The primers (MWG-biotech, DE) for calcito-
nin receptor ampliﬁcation were 50-GACAACTGCTGGCTG
AGTG-30 (sense), and 50-GAAGCAGTAGATGGTCGCAA-
30 (anti-sense). Furthermore actin mRNA was used as ahousekeeping gene control with the primers: 50-GTTACCAA
CTGGGACGACATGG-30 (sense), and 50-GATCTTGATC
TTCATGGTGC-30 (anti-sense). These lead to ampliﬁcation
of fragments of 321 bp and 762 bp, respectively.
The PCR ampliﬁcation consisted of 35 cycles of: Dena-
turation at 94(C for 1 min; annealing at 58(C for 1 min for
chondrocytes, and 62(C for human osteoclasts; extension
at 72(C for 1.5 min and a ﬁnal extension at 72(C for
7 min. As the bovine calcitonin receptor is not cloned, oligo-
nucleotides from the human sequence were used to amplify
the bovine calcitonin receptor. Human osteoclasts were
used as control to amplify the calcitonin receptor with the
human oligonucleotides. The nucleotide sequence of the
human calcitonin receptor in osteoclasts was found in Gen-
Bank (accession number AB022178).
ANIMAL EXPERIMENT
Forty female Sprague Dawley rats (Crl:CD(SD)IGS.BR)
(IFFA CREDO, S) were housed at the Animal Research Fa-
cilities at Nordic Bioscience Diagnostics and the experi-
ments were approved by the Experimental Animal
Committee, Danish Ministry of Justice (DK, approval num-
ber 192000/561-312 J2) and were performed according to
the European Standard for Good Clinical Practice. The
rats were caged in standard type III-H cages, with bedding
and nest material (Tapvei, Finland) at 18e22(C with 12-h
dark and 12-h light cycle, and the animals were given ad li-
bitum diet (Altromin 1324, Deutschland) and Milli Q water
(Millipore, DK).
STUDY DESIGN
Slow release pellets of 17-b-ethynyl-estradiol were ob-
tained from Innovative Research of America. The oral formu-
lation of salmon calcitonin was from Novartis (CH). Salmon
calcitonin is combined with the carrier 5-CNAC, which is an
eligen-technology based carrier that protects the peptide
during its gastrointestinal transition and facilitates its muco-
sal absorption19. The concentration of calcitonin was chosen
based on previous reports to be in the higher end of doses
used in rats20e23 taking into account the bio availability of
oral calcitonin is approximately 1%24. The calcitonin formu-
lations were freshly prepared daily, and immediately admin-
istered to the animals by oral gavage.
The 8-month-old rats were randomly allocated into four
groups. Standard sham operation or ovariectomy was per-
formed as previously described25. The study groups were
(1) sham (n¼ 10), (2) OVXþ slow release subcutaneously
implanted pellet 0.25 mg estrogen/60 day release (n¼ 9),
(3) OVXþ salmon calcitonin 2.0 mg/kg with 5-CNAC
150 mg/kg (n¼ 9), and (4) OVXþ 5-CNAC 150 mg/kg
(n¼ 9). The treatments were well-tolerated and three ani-
mals died from complication after ovariectomy. Body
weights of the animals were recorded at regular intervals,
and blood samples were withdrawn from fasting animals
(17 h) 2 h after medication, at seven time points until termi-
nation after 9 weeks, and were used for determination of the
serum concentration of CTX-II.
STATISTICS
Results are shown as meanþ standard error of means
(S.E.M.). Differences between mean values obtained in the
different experiments were compared by Student’s
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Pad Prism. CTX-II release from the in vivo studies was
compared by unpaired t test with Welch’s correction. Differ-
ences were considered statistically signiﬁcant if P< 0.05.
All in vitro experiments were repeated more than three
times.
Results
CALCITONIN RECEPTOR PROTEIN IDENTIFIED
ON ARTICULAR CHONDROCYTES
To investigate whether calcitonin acted directly on the
chondrocytes we assessed calcitonin receptor localization
in bovine articular cartilage by immunohistochemistry. As
seen in Fig. 1(A), the calcitonin receptor was expressed
on bovine articular chondrocytes, visualized by the intense
brown staining on the chondrocytes, and in human OA artic-
ular cartilage, Fig. 1(B). Control IgG showed no staining
[Fig. 1(C)]. Similar staining was observed with or without
stimulation of TNF-a and OSM stimulated cartilage (not
shown), suggesting that the expression is independent of
activation. Human osteoclasts were used as positive control
(data not shown).
ARTICULAR CHONDROCYTES EXPRESS
THE CALCITONIN RECEPTOR
The expression of mRNA calcitonin receptor on articular
chondrocytes was investigated by RT-PCR. The PCR anal-
ysis showed the presence of the calcitonin receptor mRNA
in isolated bovine articular chondrocytes and additionally in
human osteoclasts used as a positive control. Bands for the
calcitonin receptor of 321 bp were detected in the ethidium
bromide stained gel as seen from Fig. 2. The ampliﬁed band
for the calcitonin receptor fragment from bovine articular
cartilage was subsequently sequenced and identiﬁed as
the calcitonin receptor (data not shown). Negative control
was PCR reaction with calcitonin receptor oligonucleotides
where the reverse transcriptase was left out.
CALCITONIN SIGNALS THROUGH THE cAMP PATHWAY
The calcitonin receptor has previously been shown to ac-
tivate the adenylate cyclase resulting in increased cAMP
levels26. We therefore investigated the response of cAMPto stimulation with calcitonin in articular chondrocytes. Artic-
ular chondrocytes were exposed to calcitonin in the pres-
ence of [100 mM] IBMX, a non-speciﬁc inhibitor of cAMP
phosphodiesterases preventing the cyclic nucleotide hydro-
lysis. Calcitonin concentration-dependently and signiﬁcantly
induced the levels of cAMP in articular chondrocytes, see
Fig. 3. Calcitonin [0.01 mM] caused >40% increase in
cAMP activation (P< 0.01) and 80% increase at [1 mM] cal-
citonin compared to [100 mM] IBMX alone (P< 0.001). For-
skolin [1 mM] was used as positive control and untreated
cells as negative control.
CONCENTRATION-DEPENDENT ATTENUATION OF CYTOKINE
STIMULATED CTX-II RELEASE BY CALCITONIN
In order to investigate the direct effect of calcitonin on car-
tilage degradation we cultured articular cartilage explants in
the presence of vehicle, and the cytokines TNF-a [20 ng/ml]
and OSM [10 ng/ml] in the presence of calcitonin
[0.1e100 nM]. The conditioned medium was fully replaced
every 2nd and 3rd day. The effect of calcitonin on cartilage
degradation was evaluated by measuring the release of col-
lagen type II fragments (CTX-II) in the conditioned medium.
Figure 4 shows the concentration-dependent chondropro-
tective effect of calcitonin after 19 days of culture. Incuba-
tion with TNF-aþOSM induced a 100-fold increase in
cartilage degradation compared to control. Calcitonin treat-
ment with 10 nM and 100 nM resulted in a signiﬁcant
(P< 0.05) reduction in collagen type II degradation. Calcito-
nin treatment did not affect cell viability or cell number (data
not shown).
CALCITONIN ATTENUATES MATRIX METALLOPROTEASE
EXPRESSION
To analyze the molecular mechanism by which calcitonin
reduced collagen type II degradation, we measured prote-
ase activity in the conditioned medium at day 18 by gelati-
nase zymography. We found a marked increase in
gelatinase activity in response to stimulation with OSM
and TNF-a (Fig. 5). The molecular weight corresponds to
pro- and active-MMP-9. This increase was strongly attenu-
ated in the presence of 100 nM and 1 mM calcitonin (Fig. 5).
Incubation with 50 mM GM6001, a broad-spectrum MMP
inhibitor, completely inhibited the proteolytic activity in the
zymographs, showing that MMP activity was responsibleFig. 1. Calcitonin receptors are found in articular chondrocytes. Monoclonal antibody against the calcitonin receptor was used to localize cal-
citonin receptor. (A) Bovine articular cartilage explants positive for calcitonin receptor localization, (B) human OA articular cartilage positive for
calcitonin receptor localization, and (C) immunohistochemistry performed with a negative control mouse antibody of the same isotype, IgG2a,
on bovine articular cartilage explants. Tissue sections were counterstained with Ehrlich’s hematoxylin, and the scale bar represents 20 mM and
the pictures 60 magniﬁcation of the sections.
763Osteoarthritis and Cartilage Vol. 14, No. 8for the gelatinase activity. The section of the gel with lanes
A and B is shown.
CALCITONIN ABROGATES COLLAGEN TYPE II DEGRADATION
IN VIVO
We investigated the effects of calcitonin on cartilage turn-
over in OVX rats, by monitoring the serum CTX-II level,
which in this model has been shown to correlate with ero-
sions of articular cartilage25,27. Ovariectomyþ vehicle treat-
ment induced a signiﬁcant increase in CTX-II levels
compared to sham levels (þþþP< 0.001), from 2nd week
until after 6 weeks post-ovariectomy as seen in Fig. 6.
Administration of 2.0 mg/kg calcitonin in combination with
the vehicle, 5-CNAC 150 mg/kg, resulted in a signiﬁcant
decline in the CTX-II release compared to vehicle-
treated (***P< 0.001). Treatment with 17-b-estradiol (E2)
Fig. 2. The calcitonin receptor is expressed in articular chondro-
cytes. PCR fragments were ampliﬁed from ssDNA reverse tran-
scribed from total RNA of isolated bovine articular chondrocytes.
Human osteoclasts were used as positive control for the calcitonin
receptor. As internal positive control, oligonucleotides for actin were
used (Actin). As negative control (Neg. Co), calcitonin receptor
oligonucleotides were used and the reverse transcriptase left out.
CT-R, oligonucleotides for the calcitonin receptor.signiﬁcantly compensated for the OVX induced increase
in CTX-II release throughout the experimental period.
Discussion
The novel ﬁndings of the present study are as follows:
(1) chondrocytes expressed calcitonin receptors, (2) the
molecular mechanisms of calcitonin mediating attenuation
of cartilage degradation involved increased levels of
cAMP and attenuation of identiﬁed MMP activity, and
(3) calcitonin suppressed cartilage degradation induced by
cytokines ex vivo and suppressed cartilage loss in vivo in
OVX rats. Collectively, these ﬁndings indicate a direct chon-
droprotective effect of calcitonin, which in combination with
its inhibitory effect on subchondral bone resorption and
potential anabolic effect on chondrocytes might provide
important therapeutic beneﬁts in the treatment of degenerative
joint diseases.
Bovine articular cartilage explants cultured in the pres-
ence of the cytokines TNF-a and OSM have been shown
to be a useful ex vivo model of cartilage degradation14,28
and allow direct assessment on articular chondrocytes.
Compared to cultures of isolated chondrocytes, this
ex vivo model offers the advantage that naturally occurring
interactions between chondrocytes and the surrounding
extra-cellular matrix are preserved. The implications of the
structural integrity of the extra-cellular matrix for functional-
ity are emphasized by reports showing that certain cellular
responses can no longer be elicited when cells lose their or-
ganic links to the matrix29e32. Thus, the ex vivo articular car-
tilage explants model is the only experimental system that
allows investigation of direct effects of cytokines on carti-
lage degradation due to the presence of intact extra-cellular
matrix.
Disruption of the articular cartilage is a hallmark for the
failure of chondrocytes to maintain a homeostatic balance
between articular matrix synthesis and degradation33,34.
Several studies have provided evidence that TNF-a and
OSM, among other interleukins and cytokines, are potent
inducers of cartilage degradation in vitro and in vivo28,35e43.Fig. 3. The calcitonin receptor on articular chondrocytes signals through the cAMP pathway. Articular chondrocytes were isolated and sub-
cultured for 5 days, lifted and cultured under serum-free conditions for 24 h. The chondrocytes were hydrolyzed after 20 min stimulation
with (1) IBMX alone, (2) calcitonin in combination with IBMX, (3) forskolin and (4) forskolin in combination with IBMX. The levels of cAMP
were quantiﬁed as described in Materials and methods. Untreated cells were used as negative control. The asterisks indicate signiﬁcant dif-
ferences (**P< 0.01, ***P< 0.001).
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increased expression and activity of catabolic en-
zymes33,34,44,45. In this context, studies have indicated
that MMPs play a central role in the degradation of articular
cartilage46e49. Expression and activation of these enzymes
demark the erosion of the articular cartilage accompanied
by release of various degradation fragments from the
main components of articular matrix, of which collagen
type II and aggrecan are the best investigated47e55. In the
current study, TNF-a and OSM induced a 100-fold increase
in degradation of collagen type II compared to unstimulated
control, which calcitonin concentration-dependently in-
hibited with a maximal effect of approximately 65%.
Investigating MMP activity and expression using zymo-
graphy, we demonstrated that the inhibitory effect of calcito-
nin on cartilage degradation involves inhibition of MMP
activity, which indeed played a major role in the collagen
type II degradation induced by TNF-a and OSM28. These
ﬁndings imply that the direct chondroprotective effects of
calcitonin are attributable to a direct attenuation of the ex-
pression of the enzymes responsible for matrix degradation,
which is in line with the studies of Hellio et al.11. We showed
that TNF-a and OSM potentially induced expression of en-
zymes corresponding to the molecular weight of pro- and
active-MMP-9. This expression was strongly attenuated
by calcitonin. Detection was restricted to MMP-2 and
MMP-9, which previously have been recognized by gelati-
nase zymography15,56e59. Future studies are needed to
carefully dissect the effects of calcitonin on chondrocytes
with respect to inhibition of MMPs and other cartilage de-
generative enzymes.
Fig. 4. Direct concentration-dependent chondroprotective effect of
calcitonin. Bovine articular cartilage explants were cultured under
serum-free conditions with a combination of the cytokines TNF-a
and OSM to induce degradation of collagen type II. Every 2nd or
3rd day conditioned medium was replaced with cytokines and cal-
citonin were indicated. Control explants were cultured in medium
only. The bars show the concentration-dependent inhibition of
CTX-II release by calcitonin in the conditioned medium on day
19, adjusted for the amount of cultured cartilage. Each bar repre-
sents the mean valueþ S.E.M. from six individual wells. The asterisk
indicates signiﬁcant difference (*P 0.05).In order to establish whether the effects of calcitonin were
mediated through the calcitonin receptor, immunohisto-
chemistry on articular chondrocytes with monoclonal anti-
body against the receptor was performed. We found the
expression of the calcitonin receptor in articular chondro-
cytes in parafﬁn-embedded sections of articular cartilage
of human and bovine origin, which was conﬁrmed at RNA
expression level. We demonstrated the presence of the cal-
citonin receptor mRNA using RNA from articular chondro-
cytes by RT-PCR. RNA from osteoclasts were used as
a positive control, and the ﬁndings are in accordance with
previous reports investigating the calcitonin receptor on os-
teoclasts using the selected primers60,61. Calcitonin con-
centration-dependently induced cAMP activation showing
that the calcitonin receptor found on articular chondrocytes
is functional. Previously, cAMP has been demonstrated to
be a second messenger of the calcitonin receptor in other
tissues26. Calcitonin might mediate the chondroprotective
effects in part through cAMP and potentially through other
pathways that remain to be identiﬁed, since only a modest
increase was observed with the concentrations of calcitonin
used in this study. Collectively, these ﬁndings provide fur-
ther reason to believe that calcitonin exerts direct recep-
tor-mediated effects on MMP expression and activity in
chondrocytes underlying the inhibition of cartilage degrada-
tion, but the signaling mechanism remains undeﬁned.
To investigate the in vivo relevance of these responses,
we assessed the effects of calcitonin treatment on cartilage
degradation in vivo by measuring serum levels of CTX-II in
OVX rats. The OVX rat has previously been used as a
model of accelerated cartilage erosion25. This model more
closely resembles the increase in bone erosion and articular
cartilage degradation accompanying estrogen deﬁciency
in postmenopausal OA28, compared to the traumatic acute
anterior cruciate ligament transection (ACLT) dog
model12,13,62.
Ovariectomy induced a signiﬁcant increase in CTX-II
levels compared to sham levels (þþþP< 0.001), from week
2 except week 9. This ﬂuctuation in CTX-II levels is most
Fig. 5. Calcitonin attenuates MMP activity. Bovine articular cartilage
explants were cultured under serum-free conditions in the presence
of the cytokines TNF-a and OSM. Every 2nd and 3rd day the con-
ditioned medium was replaced with cytokines, calcitonin, or vehicle.
The conditioned medium collected at day 18 was used for gelati-
nase zymography. Lane A: vehicle, lane B: cytokines, lane C: cyto-
kinesþ 1 mM calcitonin, and lane D: cytokinesþ 100 nM calcitonin.
A corresponding gel was incubated in buffer containing the general
MMP inhibitor, GM6001, as control. The arrows indicate the molec-
ular weight of pro- and active-MMP-9.
765Osteoarthritis and Cartilage Vol. 14, No. 8Fig. 6. Calcitonin inhibits cartilage degradation in vivo. Four groups of rats: Sham, ovariectomy (OVX)þ salmon calcitonin (CT)þ vehicle,
OVXþ vehicle, and OVXþ 17-b-estradiol, entered the study at baseline, week 0. OVXþ vehicle induced a signiﬁcant increase in CTX-II levels
after 2 weeks, compared to sham levels, þþþP< 0.001, except at week 9. Oral administration of 2.0 mg/kg salmon calcitonin in combination
with the vehicle 5-CNAC 150 mg/kg, resulted in a signiﬁcant decline in the CTX-II release compared to vehicle-treated, ***P< 0.001, at all time
points. Values are meanþ S.E.M., and the CTX-II levels are compared by unpaired t test with Welch’s correction.likely due to the relative small sample size, albeit compensa-
tory mechanisms cannot be ruled out. Calcitonin completely
inhibited the estrogen deﬁciency induced increase in colla-
gen degradation suggesting highly potent in vivo effects of
calcitonin. Estrogen supplementation to OVX animals re-
sulted in a suppression in CTX-II levels below sham levels,
which in part may be due to the higher concentration of estro-
gen compared to the endogenous production of estrogen
and in part be due to a direct effect of estrogen on cartilage,
as recently presented63. As previously reported by Hoegh-
Andersen et al., levels of CTX-II decrease with age, most
likely due to decreased growth plate activity25. This was
also observed in the current experiment as all time points
displayed lower levels of CTX-II, compared to baseline,
which was signiﬁcant at weeks 4 and 6.
In this rodent model, low levels of CTX-II have been as-
sociated with preservation and structural integrity of the ar-
ticular cartilage25,27,64. Furthermore, in a large population
based study of more than 1200 subjects, high CTX-II levels
were found to be associated with increased risk of joint
space narrowing64. Although the chondroprotective effects
of calcitonin in OA patients remain to be demonstrated,
Bagger et al. recently demonstrated signiﬁcant inhibition
of not only cartilage degradation but also bone resorption
with an oral formulation of calcitonin in a 3-month interven-
tion study undertaken in healthy elderly women65. The ef-
fects of calcitonin of this oral formulation on bone turnover
have previously been published to be completely reversible
and transient19. Under the present experimental conditions
calcitonin abrogated cartilage degradation, which, however,
according to previous studies19 is reversible and normal
cartilage metabolism is restored before additional dosing,
thus allowing for periods of normal cartilage metabolism.
In addition to the direct chondroprotective effects demon-
strated in the current study, other mechanisms by which cal-
citonin might provide beneﬁts in the treatment of joint
disease, have been presented. Previous studies implicated
inhibition of subchondral bone resorption as a mechanism
by which calcitonin protects articular cartilage in the dog
ACLT model12,13. Additionally, in nonoperated knees calci-
tonin resulted in a signiﬁcant increase in the proteoglycan
content further suggesting anabolic effects. In alignment,
studies in cultured isolated chondrocytes and ex vivo ex-
plants indicate that calcitonin may stimulate collagen typeII and proteoglycan synthesis7e10,66 suggesting potential
anabolic effects of the hormone on cartilage. Finally, calci-
tonin has unique analgesic effects on bone pain, which
might relieve at least in part the symptoms accompanying
joint diseases67.
Since cartilage health appears to be both a result of artic-
ular cartilage and subchondral bone turnover, and calcitonin
has the potential to affect both, future in vivo studies are
needed to dissect the direct effect of calcitonin on cartilage
compared to the indirect effects on cartilage through atten-
uation of bone turnover. In addition we cannot rule out that
some of the reduction of the CTX-II release in rats is due to
the established effect of calcitonin on osteoclasts present in
the growth plate. However, the current data are in alignment
with a recent clinical study in postmenopausal women,
which showed a signiﬁcant reduction in CTX-II levels65.
Taken together, the present data provide strong evidence
for a direct effect of calcitonin on cartilage health, which
may be a combination of both osteoclast and chondrocyte
related events.
In conclusion, our studies provide evidence that calcito-
nin treatment carries notable chondroprotective potential
for the prevention and treatment of degenerative joint dis-
eases. Clinical studies are needed to assess the hypothe-
sized clinical beneﬁts of calcitonin for the preservation of
articular cartilage turnover and health.
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